title: [Morphometric assessment of the macula in spongiform macular edema treated with antivasoproliferative therapy].
abstract: Antivasoproliferative therapy is a pathogenetic treatment for diabetic macular edema. The objective of the study was to investigate the effect of ranibizumab on foveolar parameters in spongiform macular edema. A total of 37 patients (38 eyes) with spongiform macular edema were assessed and given antivasoproliferative therapy with ranibizumab. Optical coherence tomography showed a reduction of the total retinal thickness by 44 microm (from 306 +/- 77 microm to 262 +/- 30 microm, p < 0.05). The pigment epithelium thickness within the central area changed from 21 +/- 4 microm to 40 +/- 9 microm. The maximum decrease of the outer nuclear layer thickness was noted in 400 +/- 100 microm from foveola and averaged from 72 +/- 19 microm to 29 +/- 6 microm with its gradual increase to the periphery to 100 +/- 8 microm.
authors.forename: M M
authors.initials: MM
authors.lastname: Bikbov
authors.forename: R R
authors.initials: RR
authors.lastname: Faĭzrakhmanov
authors.forename: A L
authors.initials: AL
authors.lastname: Iarmukhametova
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab